France's Advanced Accelerator Applications (AAA) nailed down nearly $56.4 million in new financing to help advance new molecular imaging-related diagnostic tools and treatments in the U.S. and around the world. HBM Healthcare Investments led the round, which also included Tamburi Investment Partners, plus existing and new shareholders, the company said. AAA is known in Europe for positron emission tomography and single-photon emission computed tomography molecular imaging agents and related products. But it is also developing a number of personalized treatments for cancer and other diseases, and its imaging technology is meant to go hand in hand with the new drugs. More